

<b>NAME:</b>	TAK-779
<b>REPOSITORY REFERENCE:</b>	ARP968
<b>PRESENTATION:</b>	5 mg. The required concentration of TAK-779 should be prepared by dissolving in water, heated to about 75°C for five minutes, aliquoted, and frozen at -20°C.
<b>DESCRIPTION:</b>	Co-receptor antagonist. TAK-779 is a small molecule, non-peptide CCR5 antagonist with potent and selective anti HIV-1 activity.
<b>MECHANISM OF ACTION:</b>	TAK-799 inhibits HIV-1 replication at the membrane fusion stage by blocking interaction on the viral surface glycoprotein gp120 with chemokine receptor CCR5.
<b>PURITY:</b>	96.7% as determined by HPLC.
<b>MOLECULAR WEIGHT:</b>	531.14
<b>RECOMMENDED STORAGE:</b>	-20°C
<b>SOURCE:</b>	DIAIDS, NIAID. Courtesy of the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH.
<b>REFERENCES:</b>	<p>Baba, et. al. A small molecule, non-peptide CCR5 antagonist with highly potent and selective anti HIV-1 activity. <i>PNAS</i> <b>96</b>: 5698-5703, 1999.</p> <p>Dragic, et. al. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. <i>PNAS</i> <b>97</b>: 5639-5644, 2000.</p>

**NOTE:**

**Recipient agrees that the reagent (TAK-779) use is permitted only as a standard for in vitro and/or studies in animals for inhibition of HIV replication.**

**ACKNOWLEDGEMENTS:**

Distributed with permission of Takeda Chemical Industries Ltd.

Publications should acknowledge the donor of the reagent and the Programme EVA Centre for AIDS Reagents. Suggested wording can be found on our website at <http://www.nibsc.ac.uk/spotlight/aidsreagent/index.html> in the “Acknowledgements” section.

Please also ensure that you send us a copy of any papers resulting from work using reagents acquired through CFAR (this can be electronically or as a paper copy)